We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
Read MoreHide Full Article
Krystal Biotech, Inc. (KRYS - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Krystal Biotech, Inc. Strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $0.18 per share, which is a change of +110.23% from the year-ago reported number.
Over the last 30 days, two estimates have moved higher for Krystal Biotech, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 180.68%.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $1.61 per share, representing a year-over-year change of +158.33%.
The revisions trend for the current year also appears quite promising for Krystal Biotech, Inc. with five estimates moving higher over the past month compared to one negative revision. The consensus estimate has also received a boost over this time frame, increasing 352.57%.
Favorable Zacks Rank
The promising estimate revisions have helped Krystal Biotech, Inc. earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Krystal Biotech, Inc. shares have added 52.6% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
Krystal Biotech, Inc. (KRYS - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Krystal Biotech, Inc. Strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $0.18 per share, which is a change of +110.23% from the year-ago reported number.
Over the last 30 days, two estimates have moved higher for Krystal Biotech, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 180.68%.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $1.61 per share, representing a year-over-year change of +158.33%.
The revisions trend for the current year also appears quite promising for Krystal Biotech, Inc. with five estimates moving higher over the past month compared to one negative revision. The consensus estimate has also received a boost over this time frame, increasing 352.57%.
Favorable Zacks Rank
The promising estimate revisions have helped Krystal Biotech, Inc. earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Krystal Biotech, Inc. shares have added 52.6% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.